Ignite Creation Date:
2024-05-05 @ 11:53 AM
Last Modification Date:
2024-10-26 @ 9:15 AM
Study NCT ID:
NCT00156078
Status:
COMPLETED
Last Update Posted:
2021-01-25
First Post:
2005-09-07
Brief Title:
A Study To Evaluate Pregabalin In Patients With Painful Diabetic Peripheral Neuropathy DPN
Sponsor:
Pfizers Upjohn has merged with Mylan to form Viatris Inc
Organization:
Pfizer
Study Overview
Official Title:
A 14-Week Double-Blind Randomized Placebo-Controlled Multicenter Study To Evaluate The Safety And Efficacy Of Pregabalin 150mg-600mgDay Using A Flexible Optimal Dose Schedule In Patients With Painful Diabetic Peripheral Neuropathy DPN
Status:
COMPLETED
Status Verified Date:
2008-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A study of pregabalin efficacy and safety in a racially and culturally diverse group of subjects with painful diabetic peripheral neuropathy DPN
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None